Today the Health Secretary Matt Hancock has written to pharmaceutical companies to update them on progress made on human medicines supply in March 2019 “no deal scenario” with some updates to the Government planning assumptions.
Today the government has published the second Life Sciences Sector Deal. The document details both public and private sector investments into the sector, including a £1bn research and development investment from BIA member company UCB and a new partnership between government and industry using artificial intelligence to develop the next generation of treatments.
The BioIndustry Association has today announced that Action Medical Research for children will be its Charity of the Year for 2019. The partnership will be formally launched at the BIA Gala Dinner on 24 January 2019. Proceeds from a silent auction, table donations and pledges on the night will be donated to Action Medical Research for children, and attendees will hear from Simon Harriss, dad to 10-year-old Lily who has a devastating neurological condition called BPAN.
This week marked the relaunch of the All Party Parliamentary Group (APPG) for Life Sciences. Chaired by Daniel Zeichner MP, the APPG will raise awareness of UK life sciences among parliamentarians and explore the challenges and opportunities facing the sector.
A coalition from the UK’s health sector say Brexit negotiators have a responsibility to protect 500 million patients on both sides of the Channel. The group is calling on both sides to make patients and public health central to the Political Declaration for the future relationship between the UK and the EU.
In response to the announcement that UK Cabinet has approved the draft Brexit deal, BIA CEO, Steve Bates, said: "We welcome this week's progress on Brexit discussions with the initial agreement between the EU and UK on a withdrawal agreement and the political agreement on the outline of a future relationship. The BIA will now monitor and inform its members of the political debate that will ensue in the finely balanced UK parliament. There is significant detail to digest and we are engaging with members and others to understand the implications of the deal for the life sciences sector, and plan to produce a detailed briefing on this next week.
The UK Bioindustry Association (BIA) is taking a delegation of members to China for BioCentury China Healthcare Summit to promote UK science to Chinese companies and investors to encourage further collaboration between the UK and China, and will be visiting Hong Kong to explore opportunities on their stock market.
The UK BioIndustry Association (BIA) has been granted permission by the UK Supreme Court to intervene in a case that could have far-reaching impacts on the life sciences sector. The BIA is arguing that medical innovations should be patentable irrespective of how the invention is made.
The UK BioIndustry Association (BIA) and the Association of the British Pharmaceutical Industry (ABPI) have submitted a joint submission in response to the MHRA and DHSC consultation on no deal contingency legislation for medicines and devices regulation for the UK.